Beneficient (Nasdaq: BENF) — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2023, the company’s fiscal second quarter of fiscal 2024 (not calendar-year 2023 Q2). Comparative periods are the three and six months ended September 30, 2022. Beneficient completed its de-SPAC merger and converted from a Delaware limited partnership to a Nevada corporation in June 2023; earlier share and per-share figures were retroactively adjusted.
Business context
Beneficient provides liquidity financing and trust, custody, and administration services for investors in illiquid alternative assets. Its ExAlt Loans to Customer ExAlt Trusts are collateralized by investment cash flows. Those trusts are consolidated for GAAP reporting although their assets are not owned directly by Beneficient’s equity holders. As a result, reported consolidated revenue and results include trust investment marks and eliminations of operating-company interest and fee revenue; the filing cautions that the consolidated presentation does not directly represent income attributable to Beneficient shareholders.
Financial performance and position
| Metric | Quarter ended Sep. 30, 2023 | Six months ended Sep. 30, 2023 |
|---|---|---|
| Total GAAP revenue | $(42.8) million | $(45.5) million |
| Operating loss | $(381.8) million | $(1,537.7) million |
| Net loss | $(381.8) million | $(1,537.7) million |
| Net loss attributable to common shareholders | $(371.7) million | $(1,487.3) million |
| Basic and diluted loss per Class A share | $(1.45) | $(6.51) |
Revenue is negative largely because investment and financial-instrument losses are presented as revenue; a conventional operating margin is not meaningful from these consolidated figures. Management separately reports non-GAAP adjusted operating loss of $21.2 million for the quarter and $45.7 million for the six months, excluding specified items; these measures are not substitutes for GAAP results.
- Major unusual charge: Goodwill impairment was $306.7 million in the quarter and $1.403 billion for the six months, following a sustained fall in the share price and market capitalization. Goodwill declined to $964.9 million from $2.368 billion at March 31. Management reported no valuation cushion after impairment at Ben Liquidity or Ben Custody and warned further impairment may occur.
- Investment and financial-instrument marks: The quarter included a $42.8 million net loss on financial instruments, primarily a $41.8 million decline in GWG Wind Down Trust interests. Six-month investment income was $0.5 million versus a $42.2 million loss in the prior-year period; six-month financial-instrument losses were $46.2 million versus $33.1 million.
- Operating costs: Quarter employee compensation and benefits rose to $15.4 million from $10.5 million, partly reflecting equity compensation. Six-month compensation rose to $51.2 million from $22.1 million, including $15.0 million of recapitalization-related compensation. Professional services fell to $6.7 million for the quarter and $17.0 million for the six months.
- Cash flow: Six-month operating cash use was $27.4 million, investing cash provided was $25.7 million, and financing cash used was $5.5 million. Cash and restricted cash declined $7.1 million to $2.4 million; unrestricted cash at September 30 was $2.4 million. Management reported approximately $17.4 million of unrestricted cash at October 31.
- Assets, liabilities and equity: At September 30, total assets were $1.457 billion, total liabilities $273.7 million, redeemable noncontrolling interests $251.1 million, and total equity $932.3 million. Investments held by Customer ExAlt Trusts were $457.5 million, including $363.3 million of alternative assets.
- Loan portfolio and credit quality: ExAlt Loans had $552.0 million gross principal and accrued interest, a $260.2 million allowance (47.14% of loans), and $291.8 million net carrying value. Nonperforming loans were $183.5 million, or 33.25% of loans. The largest distressed collateral exposure was GWG-related; the company reported $141.7 million of allowance against loans collateralized by GWG or Wind Down Trust interests.
- Debt: September 30 balances included $102.1 million of related-party debt and $48.7 million of Customer ExAlt Trust loan payable. The HCLP-related first and second lien debt bears 9.5%; first-lien maturity was extended to September 2024, second-lien maturity to September 2027, with scheduled first-lien installments subject to a going-concern condition. The trust loan payable was repaid on October 18, 2023 through transfer of its collateral participation.
Changes versus the prior comparable periods
- Quarterly net loss widened to $381.8 million from $73.9 million, chiefly due to the $306.7 million goodwill impairment and larger financial-instrument losses. For the six months, net loss widened to $1.538 billion from $160.2 million, principally reflecting the $1.403 billion impairment.
- Quarter investment loss improved from $17.1 million to a nominal loss; six-month investment results improved from a $42.2 million loss to $0.5 million income. In contrast, six-month loss on financial instruments increased to $46.2 million from $33.1 million.
- The loan allowance increased from $129.1 million at March 31 to $260.2 million at September 30. The company adopted CECL on April 1, with an approximately $61.1 million opening adjustment to ExAlt Loan allowances for allocation purposes.
- Cash and cash equivalents fell from $8.7 million at March 31 to $2.4 million at September 30. Alternative-asset investment value declined from $385.9 million to $363.3 million, while unfunded commitments declined from $61.1 million to $58.2 million.
Liquidity, outlook and material risks
- Going concern: Management said the low cash balance, losses, and other conditions raised substantial doubt about continued operations, but concluded that its plans alleviate the doubt for the next year. Plans rely on operating cash flows and trust distributions, debt refinancing, expense reductions, and additional financing. Management also said alternative-asset distributions were below expectations and expected this pressure to continue through the remainder of fiscal 2024. Financing or refinancing may not be available on acceptable terms, or at all.
- Financing and dilution: The June 2023 SEPA gives the company the right, not obligation, to sell up to $250 million of common stock to Yorkville over 36 months, subject to conditions and share limits. The company received $1.8 million of net proceeds from the de-SPAC transaction after expenses. In October, Yorkville purchased 520,000 shares under the SEPA at $2.39 and $1.27 per share. On October 19, Beneficient drew a $25 million, three-year related-party term loan from HH-BDH LLC, affiliated with director Thomas Hicks; net proceeds were $23.4 million. The loan bears daily SOFR plus 6.5% for two years and 5.5% for the third, and is secured by substantial assets, including interests representing about 44.9% of Customer ExAlt Trust assets. Related-party fees, collateral, covenants, and potential dilution warrant attention.
- Cost reductions: The company furloughed about 30 employees in July, then in November terminated those furloughed employees and laid off 15 more, an additional approximately 10% of the November workforce. Management estimated employee costs would decline by nearly $1 million per month beginning in November; vendor and other reductions were also planned.
- Market and valuation risks: Alternative assets are largely illiquid, usually not redeemable, and dependent on fund distributions and manager-reported NAVs. The company reported $58.2 million of potential gross capital commitments; it may need to lend to trusts if they cannot meet calls. A further sustained share-price decline could cause additional goodwill impairment. The filing said the share price had been below Nasdaq’s $1 minimum bid threshold since October 17, 2023 and warned of possible delisting.
- Litigation and regulatory matters: A Wells Notice from SEC staff is a preliminary recommendation, not a finding; it concerns historical GWG-related matters and could lead to an enforcement action. The PCA litigation could expose the company to up to $350 million plus costs, although the company disputes the claims. The GWG Litigation Trust may pursue retained claims; the filing estimates potential impact from retained causes of action at approximately $155 million to $382 million. A former director’s arbitration seeks $36.3 million plus fees and punitive damages. The company cannot estimate probable outcomes or losses for these matters.
- Governance and ownership: The GWG Wind Down Trust held approximately 70% of Class A shares at September 30. Class B shares carry 10 votes each and can elect a majority of directors if the applicable ownership threshold is met. The filing highlights related-party arrangements and conflicts, including debt, services, aircraft leasing, and the October loan from an entity affiliated with a director.
- GWG exposure: GWG’s bankruptcy plan became effective August 1, converting prior GWG securities into Wind Down Trust interests. The company reported substantial historical losses on these interests and noted that their value is tied in part to Beneficient’s own stock price. The GWG Shared Services Agreement also terminated; a $15.6 million receivable allowance was written off.
Guidance: The filing provides no quantified revenue or earnings guidance. Management’s outlook is conditional on growth, refinancing, capital raising, and improved operating cash flows. It expects no material capital expenditures through the remainder of fiscal 2024.
Most important facts for investors to verify
- Whether post-quarter cash, the $25 million term loan, insurance reimbursements, and SEPA sales provide adequate liquidity after debt service and operating needs.
- ExAlt Loan performance, the high allowance and nonperforming-loan levels, collateral values, and actual cash distributions from illiquid funds.
- Whether further share-price declines trigger additional goodwill impairment or jeopardize Nasdaq listing compliance.
- Potential dilution and sale pressure from the SEPA, registered resales, preferred-stock conversions, and the GWG Wind Down Trust’s large shareholding.
- Developments in the SEC Wells process, PCA litigation, GWG Litigation Trust claims, and the arbitration, including any changes to estimated exposure.
- Terms, covenants, collateral, repayment schedule, and related-party economics of the HH-BDH loan, alongside the HCLP facilities.
- Whether planned staffing and vendor reductions achieve the stated savings without impairing business execution or customer activity.